Representing Anthem, Inc. in more than 100 class action lawsuits that have been filed around the country related to their cyberattack. 

National product liability counsel for Bristol-Myers Squibb in a mass tort involving allegations that Abilify causes compulsion gambling.

Celgene on its US$9bn acquisition of Juno Therapeutics and US$7bn acquisition of Impact Biomedicines.

Advising a drug company on strategies for obtaining orphan drug approval and working with scientific and regulatory groups to draft and submit designation request.

Eli Lilly in its European patent disputes concerning its oncology product, pemetrexed.

LabCorp on its US$1.2bn acquisition of Chiltern, a specialty contract research organization focusing on clinical research services for the pharmaceutical and medical device industries.

Instrumental in persuading FDA to change longstanding regulatory position on awarding exclusivity to fixed-dose combination products, benefitting Gilead’s products in the HIV and Hepatitis C fields.

Advising a leading pharma company on its innovative approach regarding digital health offerings.

Advising a U.S. medical device company on regulatory and commercial issues regarding the market launch of a gene test in 24 European countries.

Merck Sharp & Dohme in Hatch-Waxman actions against Hospira and Sandoz in relation to Merck’s antibiotic drug, Invanz®.

Representing Novartis in an exclusive global collaboration agreement with the University of Pennsylvania to develop and commercialize immunotherapies for cancer.

Representing Novartis in its landmark portfolio transformation transactions with GlaxoSmithKline and Eli Lilly valued at more than US$23bn.

Pfizer on its new venture, SpringWorks Therapeutics, a mission-driven medicines company dedicated to developing innovative potential new treatments for underserved patient communities.

Pharmaceutical and biologics companies in connection with numerous federal and state investigations of sales and marketing, pricing, Medicaid rebate, FDCA promotional issues, and cGMP compliance.

Provider networks in multiple investigations of their clinical integration and joint negotiations with health plans by federal and/or state antitrust enforcers.

Representing TESARO in its US$101m Series B financing, its IPO, and all of its follow-on equity financings and US$165m notes financing.

TÜV Rheinland in its global defense against liability claims resulting from allegedly inappropriate certification of breast implant manufacturer P.I.P.

Hospital transactions for Vanderbilt University, UW Health, UC Health, University of Minnesota, Saint Louis University, Georgetown University, University of Miami, the State University of New York, and more.